Financial Performance3Q24 earnings per share (EPS) of $6.61 exceeded expectations, driven by higher revenues and reduced operational expenses.
Pipeline DevelopmentJazz Pharma reported a positive update on the pipeline with the initiation of the Phase 1 study for JZP441, suggesting future growth prospects.
Product GrowthXywav for narcolepsy showed impressive growth of 10%, following a 5-6% growth earlier, indicating strong market performance.